Pre-Conference Workshops

It is clear that inhibiting the complement system could be the key to life-changing therapies for patients with complement-driven renal diseases such as C3 glomerulopathy and aHUS. However, further studies are needed to understand the best therapeutic strategies that could improve prognosis.
Attend this workshop to examine the latest opportunities in identifying complement targeting therapies.

Highlights include:

  • Interrogating the shared and distinct mechanisms by which complement is activated in
    immune-mediated diseases
  • Delineating which pathways to target for therapeutic intervention
  • Analyzing opportunities to use therapeutic complement inhibitors to treat kidney diseases

Workshop Leaders

Scott Rottinghaus Alexion

Scott Rottinghaus
Vice President &
Head Of Clinical
Development,
Hematology &
Nephrology
Alexion Pharmaceuticals

Julie Williams AstraZeneca

Julie Williams
Director, Bioscience
CKD
AstraZeneca 

Nader Najafian Alexion

Nader Najafian
Executive Director,
Clinical Development
Sciences
Alexion

William Smith Alexion

William Smith
Executive Director,
Nephrology Clinical
Development Sciences
Alexion

Workshop B: From Bench to Bedside: Paving the Way for Clinical Success in Lupus Nephritis

11.30 am - 2.30 pm

While lupus nephritis has been an area of significant clinical setbacks for decades, recent progress in drug development to preserve kidney function has been unprecedented. The recent approvals of therapeutics herald a renaissance for lupus nephritis trials, presenting a significant opportunity to build on clinical successes and explore avenues for implementing precision medicine.
Join this workshop to evaluate cutting-edge trial design and opportunities to reduce progression in long-term organ damage.

Highlights include:

  • Navigating opportunities for precision medicine and personalized treatments in lupus
  • Analyzing updates in combination therapies for lupus nephritis
  • Regulatory perspective on drug development for lupus: considering acceptable endpoints

Workshop Leaders

FDA for Nikolay

Nikolay Nikolove
Director of the Division
of Rheumatology &
Transplant Medicine
FDA

Brad Rovin Ohio

Brad Rovin
Director, Division of
Nephrology
Ohio State
University

Richard Furie

Richard Furie
Chief, Division of
Rheumatology
Northwell Health

Workshop C: Elucidating the Pathogenesis of IgA Nephropathy & Learning from Clinical Updates to Identify Potential Therapeutic Targets in IgAN

3.00 pm - 6.00 pm

IgA nephropathy is the most common primary glomerulonephritis but remains a significant unmet medical need with no targeted therapies available. Recent translational research has generated greater insight into potential therapeutic targets for this complex autoimmune disease, however, translating findings into clinical practice is challenging.
Get involved in this workshop to keep up to date with the latest in clinical progress in IgAN, and discuss opportunities for future targeted therapies.

Highlights include:

  • Identifying patients that are most likely to progress to end-stage kidney disease
  • Reflecting on recent successes in clinical trials to understand which mechanisms to target
  • Analysis of primary endpoints for IgA and obtaining Orphan Drug Designation

Workshop Leader

Jonathan Barratt compressed

Jonathan Barratt
The Mayer Professor
of Renal Medicine
University of Leicester